HK1207666A1 - Rnai pharmaceutical composition capable of suppressing expression of kras gene kras rnai - Google Patents

Rnai pharmaceutical composition capable of suppressing expression of kras gene kras rnai

Info

Publication number
HK1207666A1
HK1207666A1 HK15108285.0A HK15108285A HK1207666A1 HK 1207666 A1 HK1207666 A1 HK 1207666A1 HK 15108285 A HK15108285 A HK 15108285A HK 1207666 A1 HK1207666 A1 HK 1207666A1
Authority
HK
Hong Kong
Prior art keywords
rnai
kras
pharmaceutical composition
composition capable
suppressing expression
Prior art date
Application number
HK15108285.0A
Other languages
English (en)
Chinese (zh)
Inventor
Tomoyuki Naoi
Takeshi Kuboyama
Junichi Enokizono
Toshihiko Ishii
Akihiro Tokunaga
Kentarou Hatanaka
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of HK1207666A1 publication Critical patent/HK1207666A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK15108285.0A 2012-07-16 2015-08-26 Rnai pharmaceutical composition capable of suppressing expression of kras gene kras rnai HK1207666A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261671963P 2012-07-16 2012-07-16
PCT/JP2013/069322 WO2014013995A1 (ja) 2012-07-16 2013-07-16 KRAS遺伝子発現抑制RNAi医薬組成物

Publications (1)

Publication Number Publication Date
HK1207666A1 true HK1207666A1 (en) 2016-02-05

Family

ID=49948821

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15107660.7A HK1207113A1 (en) 2012-07-16 2015-08-08 Rnai pharmaceutical composition capable of suppressing expression of kras gene kras rnai
HK15108285.0A HK1207666A1 (en) 2012-07-16 2015-08-26 Rnai pharmaceutical composition capable of suppressing expression of kras gene kras rnai

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK15107660.7A HK1207113A1 (en) 2012-07-16 2015-08-08 Rnai pharmaceutical composition capable of suppressing expression of kras gene kras rnai

Country Status (10)

Country Link
US (1) US9913907B2 (xx)
EP (1) EP2873732A4 (xx)
JP (1) JP6272226B2 (xx)
CN (1) CN104471062A (xx)
AU (1) AU2013291125A1 (xx)
CA (1) CA2878314A1 (xx)
HK (2) HK1207113A1 (xx)
SG (1) SG11201502954TA (xx)
TW (1) TW201408324A (xx)
WO (1) WO2014013995A1 (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101791702B1 (ko) * 2009-04-03 2017-10-30 다이서나 파마수이티컬, 인크. 비대칭 이중가닥 ｒｎａ에 의한 ｋｒａｓ의 특이적 저해를 위한 방법 및 조성물
US20170101639A1 (en) * 2014-06-04 2017-04-13 Kyowa Hakko Kirin Co., Ltd. RNAi PHARMACEUTICAL COMPOSITION FOR SUPPRESSING EXPRESSION OF CKAP5 GENE
CA2959358C (en) * 2014-06-30 2022-07-26 Kyowa Hakko Kirin Co., Ltd. Cationic lipid
JP2019535839A (ja) 2016-11-29 2019-12-12 ピュアテック ヘルス エルエルシー 治療剤の送達のためのエクソソーム
AU2018214556A1 (en) * 2017-02-01 2019-08-15 Modernatx, Inc. Immunomodulatory therapeutic mRNA compositions encoding activating oncogene mutation peptides
CA3061322A1 (en) * 2017-04-28 2019-10-23 Kyowa Kirin Co., Ltd. Oligonucleotide derivative or salt thereof
JP7419268B2 (ja) * 2018-03-02 2024-01-22 エリシオ セラピューティクス， インク． 変異ｋｒａｓ配列及び脂質を含む化合物並びにその使用
CN111534520A (zh) * 2020-05-27 2020-08-14 深圳市疾病预防控制中心（深圳市卫生检验中心、深圳市预防医学研究所） 特异抑制K-ras基因表达的慢病毒和重组载体构建及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1270198A (en) 1984-08-08 1990-06-12 Marcel B. Bally Encapsulation of antineoplastic agents in liposomes
AU594654B2 (en) 1985-01-07 1990-03-15 Syntex (U.S.A.) Inc. 1,2 dialkoxy-omega-trialkylammonium cationic surfactants
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
JP2923296B2 (ja) 1988-11-14 1999-07-26 株式会社ビタミン研究所 細胞への遺伝子導入法
JPH0696670B2 (ja) 1988-11-16 1994-11-30 日本ポリウレタン工業株式会社 反応性安定化ポリオール組成物
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6469158B1 (en) 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5804683A (en) 1992-05-14 1998-09-08 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA with alkylamine
US5977343A (en) 1992-05-14 1999-11-02 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
CA2169645A1 (en) 1993-09-02 1995-03-09 Nassim Usman Non-nucleotide containing enzymatic nucleic acid
US5889136A (en) 1995-06-09 1999-03-30 The Regents Of The University Of Colorado Orthoester protecting groups in RNA synthesis
CA2237316C (en) 1995-11-30 2012-06-26 Vical Incorporated Complex cationic lipids
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
WO1998051278A2 (en) * 1997-05-14 1998-11-19 Inex Pharmaceuticals Corporation High efficiency encapsulation of charged therapeutic agents in lipid vesicles
TWI225412B (en) 1997-06-23 2004-12-21 Sequus Pharm Inc Liposome-entrapped polynucleotide composition and method
US6111086A (en) 1998-02-27 2000-08-29 Scaringe; Stephen A. Orthoester protecting groups
WO2000030444A1 (en) * 1998-11-25 2000-06-02 Vanderbilt University Cationic liposomes for gene transfer
AU2001249622B2 (en) 2000-03-30 2007-06-07 Massachusetts Institute Of Technology RNA sequence-specific mediators of RNA interference
EP1323415B1 (en) 2000-10-04 2010-01-13 Kyowa Hakko Kirin Co., Ltd. Method of coating fine particle with lipid film
US20020132788A1 (en) 2000-11-06 2002-09-19 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
JP2005508306A (ja) 2001-07-23 2005-03-31 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 哺乳類における遺伝子発現のＲＮＡｉによる阻害に関する方法および組成物
CA2569664C (en) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
JPWO2006080118A1 (ja) 2005-01-28 2008-06-19 協和醗酵工業株式会社 標的遺伝子の発現を抑制する組成物
GB0505969D0 (en) 2005-03-23 2005-04-27 Novartis Ag Organic compounds
JP2010519912A (ja) * 2007-03-02 2010-06-10 エムディーアールエヌエー，インコーポレイテッド Ｒａｓ遺伝子の発現を抑制するための核酸化合物およびその使用
EP3100718B1 (en) * 2008-01-02 2019-11-27 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
WO2010080129A2 (en) * 2008-12-18 2010-07-15 Dicerna Pharmaceuticals, Inc. Extended dicer substrate agents and methods for the specific inhibition of gene expression
KR101791702B1 (ko) 2009-04-03 2017-10-30 다이서나 파마수이티컬, 인크. 비대칭 이중가닥 ｒｎａ에 의한 ｋｒａｓ의 특이적 저해를 위한 방법 및 조성물
EP2567951B1 (en) 2010-04-28 2018-09-19 Kyowa Hakko Kirin Co., Ltd. Cationic lipid
EP2792368A4 (en) 2011-12-12 2015-09-30 Kyowa Hakko Kirin Co Ltd LIPID NANOPARTICLES WITH COMBINATIONS OF CATIONIC LIPIDES
JP6182457B2 (ja) 2011-12-12 2017-08-16 協和発酵キリン株式会社 カチオン性脂質を含有するドラックデリバリーシステムのための脂質ナノ粒子

Also Published As

Publication number Publication date
US9913907B2 (en) 2018-03-13
JP6272226B2 (ja) 2018-01-31
US20140044755A1 (en) 2014-02-13
TW201408324A (zh) 2014-03-01
EP2873732A4 (en) 2016-03-23
JPWO2014013995A1 (ja) 2016-07-07
WO2014013995A1 (ja) 2014-01-23
HK1207113A1 (en) 2016-01-22
AU2013291125A1 (en) 2015-01-22
CN104471062A (zh) 2015-03-25
CA2878314A1 (en) 2014-01-23
EP2873732A1 (en) 2015-05-20
SG11201502954TA (en) 2015-05-28

Similar Documents

Publication Publication Date Title
IL281295A (en) Preparations and methods for inhibiting expression of the ALAS1 gene
HK1204770A1 (en) Compartmentalized method of nucleic acid delivery and compositions and uses thereof
HK1211316A1 (en) Mirna modulators of thermogenesis mirna
EP2677865A4 (en) BROMODOMAIN INHIBITORS AS MODULATORS OF GENE EXPRESSION
EP2691121A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TMPRSS6 GENE
HK1207666A1 (en) Rnai pharmaceutical composition capable of suppressing expression of kras gene kras rnai
EP2855680A4 (en) COMPOSITIONS AND METHODS FOR SILENCING GENE EXPRESSION
HK1209621A1 (en) Inhibitors of the mir-15 family of micro-rnas mir-15 rna
EP2917314A4 (en) OLIGOMERATZUSAMMENSETZUNG
SI2691083T1 (sl) Farmacevtski sestavek sitagliptina
ZA201504442B (en) Regulation of gene expression
HRP20180567T1 (hr) Farmaceutski pripravak omeprazola
HK1214160A1 (zh) 抑制劑的藥物組合物
PT3524260T (pt) Composições farmacêuticas para o tratamento de inapetência
HK1201066A1 (en) Pyranopyridone inhibitors of tankyrase
ZA201402165B (en) Compositions of lopinavir
GB201100786D0 (en) Pharmaceutical compositions of immunosuppressants
EP2884964A4 (en) PHARMACEUTICAL COMPOSITION OF PROPOFOL
EP2739738A4 (en) USE OF INTEGRASE FOR TARGETED GENE EXPRESSION
IL233445A0 (en) Methods and preparations for gene transfer
IL233879A0 (en) Dry powdered dnase i preparations
GB201104632D0 (en) Use of medicament